Non-invasive assessment of pulmonary blood flow using an inert gas rebreathing device in fibrotic lung disease.

BACKGROUND AND AIMS Pulmonary hypertension (PH) is increasingly recognised in patients with diffuse lung disease, and is associated with increased mortality. Cardiac output (CO) is a prognostic marker in PH. Non-invasive assessment of pulmonary blood flow (PBF(INNOCOR)) with the inert gas rebreathing Innocor device has been validated against CO in PH, but not in PH associated with parenchymal lung disease. PBF(INNOCOR) may be less accurate in patients with lung disease because of intrapulmonary shunting and/or incomplete gas mixing. Our aim was to determine the variability of PBF(INNOCOR) in normal subjects, before evaluating PBF(INNOCOR) in diffuse lung disease against CO measured by the indirect Fick method (CO(FICK)) at right heart catheterisation (RHC). METHODS AND RESULTS 23 normal subjects had lung volume measurements by a constant-volume body plethysmograph and three consecutive PBF(INNOCOR) measurements on the same day. 20 subjects returned for repeat assessment. PBF(INNOCOR) had good intrasession repeatability (coefficient of variation (CV)=6.57%) and intersession reproducibility (mean CO difference=0.13; single determinant SD=0.49; CV=9.7%). 28 consecutive patients with lung fibrosis referred for RHC had PBF(INNOCOR) measured within 24 h of RHC. There was good agreement between CO(FICK) and PBF(INNOCOR), with no evidence of systematic bias (mean CO(FICK) 4.3+/-1.0; PBF(INNOCOR) 4.0+/-1.2l/ min; p=0.07). Bland-Altman analysis revealed a mean difference of -0.32 and limits of agreement of -2.10 to +1.45. CONCLUSION Non-invasive PBF measured by the inert gas rebreathing Innocor device has good intrasession repeatability and intersession reproducibility. In diffuse lung disease, CO can be accurately and non-invasively measured by the Innocor device.